Ajanta Pharma gains on launch of generic SINGULAIR capsules in the US

The company has launched Montelukast Sodium oral granules (4mg), a bioequivalent generic version of SINGULAIR Granules, in the US market.

Shares of Ajanta Pharma were up nearly 2% at Rs 1,358 on the Bombay Stock Exchange, after the company said announced the launch of Montelukast Sodium oral granules (4mg), a bioequivalent generic version of SINGULAIR Granules, in the US market.

The Montelukast Granules are offered in cartons containing 30 individuals sachets, the company said in release. The drug is dispensed to prevent asthma attacks.

The approval and launch of the Monteklukast Granules is part of an ever-growing portfolio that Ajanta Pharma has developed for the US market, the release added.

The release also said that the US Food & Drug Administration (USFDA) has granted five ANDA approvals and two ANDA tentative approvals adding that an additional 19 ANDAs are pending approval from the USFDA.

The stock opened at Rs 1366 and touched a high of Rs 1,370. At 12:40pm, over 198,000 shares were traded on both the stock exchanges